Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Itti

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
Blood|November 19, 2020
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSASteven Le Gouill, Hervé Ghesquières, Lucie Oberic, et al.
Blood|June 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatmentAlexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP TrialVincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
The Lancet. Oncology|November 7, 2017
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trialValérie Vilgrain, Helena Pereira, Eric Assenat, et al.
Blood Advances|March 3, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaVincent Camus, Thierry Molina, Fabienne Desmots, et al.
Archives of Cardiovascular Diseases|August 28, 2023
Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in FranceThibaud Damy, Amira Zaroui, Marie de Tournemire, et al.
The Lancet. Gastroenterology & Hepatology|February 23, 2025
[<sup>18</sup>F]fluorodeoxyglucose and [<sup>18</sup>F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre studyJean-Charles Nault, Marouane Boubaya, Myriam Wartski, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
Blood|November 19, 2020
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSASteven Le Gouill, Hervé Ghesquières, Lucie Oberic, et al.
Blood|June 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatmentAlexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP TrialVincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
The Lancet. Oncology|November 7, 2017
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trialValérie Vilgrain, Helena Pereira, Eric Assenat, et al.
Blood Advances|March 3, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaVincent Camus, Thierry Molina, Fabienne Desmots, et al.
Archives of Cardiovascular Diseases|August 28, 2023
Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in FranceThibaud Damy, Amira Zaroui, Marie de Tournemire, et al.
The Lancet. Gastroenterology & Hepatology|February 23, 2025
[<sup>18</sup>F]fluorodeoxyglucose and [<sup>18</sup>F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre studyJean-Charles Nault, Marouane Boubaya, Myriam Wartski, et al.
Pageof 15